Active Biotech regains global rights to development and commercialization of laquinimod
05 Setembro 2018 - 3:30AM
PRESS RELEASE
Lund Sweden, September 5, 2018
- Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that
it regains the global development and commercialization rights to
laquinimod from Teva Pharmaceutical Industries Ltd. Teva's decision
to return the rights is based on the fact that Teva does not intend
to continue the clinical development of laquinimod. As a
consequence of the decision and in accordance with the license
agreement, the full rights, including all data generated in the
comprehensive preclinical and clinical development program that
Teva has conducted since 2004, will revert to Active Biotech.
Laquinimod, an orally administered small molecule
has primarily been developed as a potential treatment of
neurodegenerative diseases such as multiple sclerosis (MS) and
Huntington's disease (HD). The global development program that
evaluated laquinimod includes three completed phase III studies in
relapsing remitting MS (RRMS) and one phase II study in HD.
Laquinimod showed consistent effect on both relapse related
endpoints and MRI parameters in RRMS. A pronounced effect on brain
atrophy was demonstrated in both RRMS and HD patients. In addition
a good safety profile has been demonstrated throughout the clinical
program.
"We are grateful for the good collaboration with
Teva and for the broad development program that has been carried
out for laquinimod. The pronounced effect of laquinimod on brain
atrophy demonstrated in both RRMS and HD patients supports our
belief in the potential of laquinimod as a possible treatment for
neurodegenerative diseases, a disease area where the medical need
remains high. Therefore, we will assess all opportunities for a
continuation of the development of laquinimod" said Helén Tuvesson,
CEO of Active Biotech.
About laquinimod
Laquinimod is a once-daily oral, investigational, selective aryl
hydrocarbon receptor (AhR) activator targeting neurodegeneration
and inflammation with a novel mechanism of action. Laquinimod has
primarily been developed for the treatment of multiple sclerosis
(MS) and Huntington disease (HD) but clinical studies have also
been conducted in Crohn's disease and Lupus. The global development
program that evaluated laquinimod includes three completed phase
III studies in relapsing remitting MS; the ALLEGRO, BRAVO and
CONCERTO studies, as well as the phase II study ARPEGGIO in primary
progressive MS. In the phase II study LEGATO-HD, laquinimod was
studied in the rare neurodegenerative disease Huntington's disease,
a disease in which laquinimod has been granted orphan drug status
in US.
Lund, September 5, 2018
Active Biotech AB (publ)
Helén Tuvesson
President and CEO
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Helén Tuvesson, CEO
Tel +46 46 19 21 56
Active Biotech AB (publ)
(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties in development for neurodegenerative diseases. ANYARA,
an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit http://www.activebiotech.com/en for more
information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Active Biotech is obligated to
make public the information pursuant to the EU Market Abuse
Regulation. This information was provided to the media, through the
agency of the contact person set out above, for publication on
September 5, 2018 at 8:30 a.m. CET.
Active Biotech regains rights to
laquinimod
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024